Echo IQ finalized convertible note and option agreements with medical imaging leader Pro Medicus. This move executes a strategic partnership framework first announced in June 2026.
Pro Medicus will invest up to A$20 million in the diagnostic technology company. The funding includes an initial A$10 million through secured convertible notes.
Echo IQ may receive an additional A$10 million following FDA clearance of its EchoSolv HF software.
The agreement establishes Pro Medicus as a reseller of Echo IQ’s AI-powered cardiac products in the United States. This partnership provides access to an extensive hospital network to accelerate commercial adoption.